Winslow Evans & Crocker’s Blueprint Medicines BPMC Stock Holding History

Winslow Evans & Crocker’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-246	Closed	-$20K	–	1121
2019 Q4	$20K	Hold	246	–	–	0.01%	657
2019 Q3	$18K	Hold	246	–	–	0.01%	662
2019 Q2	$24K	Buy	246 +36	+17%	+$2.97K	0.01%	636
2019 Q1	$18K	Buy	210 +134	+176%	+$9.9K	0.01%	681
2018 Q4	$6K	Hold	76	–	–	﹤0.01%	858
2018 Q3	$6K	Buy	+76	New	+$5.28K	﹤0.01%	885

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Winslow Evans & Crocker's BPMC Position: Q1 2020 in Review

Winslow Evans & Crocker sold out of Blueprint Medicines (BPMC) in Q1 2020, closing a stake of 246 shares — an estimated $20K sold.

Winslow Evans & Crocker first reported a position in BPMC in Q3 2018 and held it in 6 quarters. The position peaked at $24K in Q2 2019. 213 funds tracked by Wall St. Rank hold BPMC as of Q1 2020.

Winslow Evans & Crocker reported no remaining Blueprint Medicines position as of Q1 2020 after selling out during the quarter.
Winslow Evans & Crocker sold 246 Blueprint Medicines shares in Q1 2020, an estimated $20K.
Winslow Evans & Crocker first reported a position in Blueprint Medicines in Q3 2018 and held it in 6 quarters.
Winslow Evans & Crocker's Blueprint Medicines position peaked at $24K in Q2 2019.
213 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2020.

Based on Winslow Evans & Crocker's 13F filing for Q1 2020, filed 20 Apr 2020.